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Glucose-6-Phosphate Regulates Hepatic 
Bile Acid Synthesis in Mice
Joanne A. Hoogerland,1 Yu Lei,1 Justina C. Wolters,1 Jan Freark de Boer,1,2 Trijnie Bos,1 Aycha Bleeker,1 Niels L. Mulder,1  
Theo H. van Dijk,2 Jan A. Kuivenhoven,1 Fabienne Rajas,3 Gilles Mithieux,3 Rebecca A. Haeusler,4 Henkjan J. Verkade,1  
Vincent W. Bloks,1 Folkert Kuipers,1,2 and Maaike H. Oosterveer1
It is well established that, besides facilitating lipid absorption, bile acids act as signaling molecules that modulate 
glucose and lipid metabolism. Bile acid metabolism, in turn, is controlled by several nutrient-sensitive transcrip-
tion factors. Altered intrahepatic glucose signaling in type 2 diabetes associates with perturbed bile acid synthesis. 
We aimed to characterize the regulatory role of the primary intracellular metabolite of glucose, glucose-6-phosphate 
(G6P), on bile acid metabolism. Hepatic gene expression patterns and bile acid composition were analyzed in mice 
that accumulate G6P in the liver, that is, liver-specific glucose-6-phosphatase knockout (L-G6pc−/−) mice, and 
mice treated with a pharmacological inhibitor of the G6P transporter. Hepatic G6P accumulation induces sterol 
12α-hydroxylase (Cyp8b1) expression, which is mediated by the major glucose-sensitive transcription factor, carbohy-
drate response element-binding protein (ChREBP). Activation of the G6P-ChREBP-CYP8B1 axis increases the rel-
ative abundance of cholic-acid–derived bile acids and induces physiologically relevant shifts in bile composition. The 
G6P-ChREBP–dependent change in bile acid hydrophobicity associates with elevated plasma campesterol/cholesterol 
ratio and reduced fecal neutral sterol loss, compatible with enhanced intestinal cholesterol absorption. Conclusion: 
We report that G6P, the primary intracellular metabolite of glucose, controls hepatic bile acid synthesis. Our work 
identifies hepatic G6P-ChREBP-CYP8B1 signaling as a regulatory axis in control of bile acid and cholesterol 
metabolism. (Hepatology 2019;70:2171-2184).
Bile acids facilitate absorption of dietary lipids and fat-soluble vitamins in the intestine, but also act as signaling molecules that control 
glucose, lipid, and energy metabolism.(1) Bile acid 
metabolism is known to be perturbed in conditions 
of uncontrolled hyperglycemia and insulin resistance 
(IR).(2,3) Bile acid synthesis from cholesterol occurs 
exclusively in the liver and comprises multiple bio-
chemical reactions initiated by cholesterol 7α-hydrox-
ylase (CYP7A1), the rate-controlling enzyme in the 
“classic” pathway of primary bile acid synthesis. Sterol 
12α-hydroxylase (CYP8B1) subsequently generates 
3α,7α,12α-trihydroxy-5β-cholan-24-oic acid (cholic 
acid; CA) as an end product.(2,4,5) As a consequence, 
hepatic CYP8B1 activity determines the contribution 
of CA produced in the classic pathway relative to 
3α,7α-dihydroxy-5β-cholan-24-oic acid (chenodeoxy-
cholic acid; CDCA). CDCA, in contrast to CA, can 
also be generated by an “alternative” pathway starting 
with 27-hydroxylation of cholesterol.(6) CDCA is 
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C4, 7α-hydroxy-4-cholesten-3-one; CA, cholic acid (3α,7α,12α-trihydroxy-5β-cholan-24-oic acid); CDCA, chenodeoxycholic acid (3α,7α-
dihydroxy-5β-cholan-24-oic acid); ChIP, chromatin immunoprecipitation; ChREBP, carbohydrate response element-binding protein (Mlxipl); 
Cyp2c70, cytochrome P450, family 2, subfamily c, polypeptide 70; Cyp7a1, cholesterol 7α-hydroxylase; Cyp7b1, oxysterol 7α-hydroxylase; Cyp8b1, 
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efficiently converted to hydrophilic C6-hydroxylated 
muricholic acids (MCAs) in rodents, but not in 
humans.(6) Primary bile acid species are secreted into 
the intestine, where they can be converted by micro-
bial actions to secondary bile acids with distinct phys-
icochemical properties(6) that determine their efficacy 
to promote fat and cholesterol absorption as well as 
their signaling functions.(1)
Bile acid synthesis is increased during postprandial 
periods and reduced upon fasting.(7) Insulin and glu-
cose have both been reported to induce the expression 
of CYP7A1 in cultured hepatocytes.(8,9) Moreover, 
insulin suppresses whereas glucose induces the expres-
sion of Cyp8b1.(9,10) Insulin-induced suppression of 
Cyp8b1 is mediated by the transcription factor, fork-
head box protein O1 (FOXO1).(4) Under insulin- 
resistant conditions, constitutive FOXO1 activation 
shifts the composition of the bile acid pool toward 
an increased contribution of CA and its hydrophobic 
microbial metabolite, 3α,12α-dihydroxy-5β–cholan-
24-oic acid (deoxycholic acid; DCA).(4) Accordingly, 
we and others have shown that IR is associated with 
an increase in CA synthesis(2,4,5) and a more hydro-
phobic bile acid pool in humans.(2) IR is generally 
associated with hyperglycemic episodes, enhancing 
intrahepatic glucose metabolism.(11,12)
Here, we characterized the direct regulatory role of 
intrahepatic glucose on bile acid synthesis. After being 
taken up by hepatocytes, glucose is immediately con-
verted into glucose-6-phosphate (G6P), the primary 
intracellular metabolite of glucose that acts as a sig-
naling molecule.(12) Glycogen storage disease type 1 
(GSD I) is an inborn error of carbohydrate metabo-
lism caused by mutations in the glucose-6-phosphatase 
(glucose-6-phosphatase, catalytic subunit; G6PC) gene 
(GSD Ia) or the glucose-6-phosphate transporter, 
SLC37A4 (GSD Ib). GSD I is characterized by a strong 
accumulation of G6P inside hepatocytes and, impor-
tantly, low fasting glucose and insulin levels.(13) We took 
advantage of this unique feature to evaluate the effects 
of intracellular glucose versus blood glucose and insulin 
and hence to selectively establish the effects of intra- 
versus extrahepatic glucose on bile acid metabolism. 
Our data show that, in mice, intrahepatic G6P regu-
lates bile acid metabolism by a carbohydrate response 
element-binding protein (ChREBP; also known as 
Mlxipl)-dependent induction of CYP8B1, resulting 
in an increased hydrophobicity of biliary bile acids 
and reduced fecal cholesterol loss. On the other hand, 
hepatic CYP7A1 expression was regulated by extrahe-
patic (blood) glucose rather than intrahepatic G6P.
Materials and Methods
aNIMalS
Male adult (8-12 weeks) B6.G6pclox/lox and 
B6.G6pclox/lox.SAcreERT2/w mice,(14) male L-FoxO1,3,4−/− 
and L-FoxO1,3,4+/+ mice (18-20 weeks old),(15) and 
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C57BL/6 mice (12-13 weeks old, local breeding) were 
housed in a light- and temperature-controlled facil-
ity and fed a standard laboratory chow diet (RMH-B; 
AB-diets, Woerden, The Netherlands). Liver-specific 
G6pc-deficient mice (L-G6pc−/−) and wild-type (WT) lit-
termates (L-G6pc+/+) were generated as described.(14) For 
tissue collection, mice were sacrificed by cardiac puncture 
10 days after the last tamoxifen injection in nonfasted 
conditions, unless stated otherwise. In separate experi-
ments requiring bile collection, mice were anesthetized 
by intraperitoneal injection of Hypnorm (10 mL/kg; 
Janssen Pharmaceuticals, Tilburg, The Netherlands) and 
diazepam (10 mg/kg; Actavis, Baarn, The Netherlands), 
the bile duct was ligated, the gallbladder was cannulated, 
and bile was collected for 30 minutes.
Male L-FoxO1,3,4−/−, L-FoxO1,3,4+/+ mice and 
C57BL/6 mice were equipped with a permanent cath-
eter in the right jugular vein for infusions and were 
allowed a recovery period of at least 4 days. Mice were 
kept in experimental cages during the experiment and 
the preceding fasting period, allowing frequent col-
lection of tail blood samples. After overnight fasting, 
mice were infused for 6 hours with S4048 (a gener-
ous gift from Sanofi-Aventis, Frankfurt, Germany, 5.5 
mg/mL of phosphate-buffered saline (PBS) with 6% 
dimethyl sulfoxide at 0.135 mL/h) or vehicle. Blood 
glucose concentrations were measured in tail blood 
every 30 minutes during the experiment. All experi-
mental procedures were approved by the Institutional 
Animal Care and Use Committee of the University of 
Groningen.
CoNStRUCtIoN, pRoDUCtIoN, 
aND IN VIVO tRaNSDUCtIoN 




To construct the self-complementary (scAAV) ade-
no-associated virus (AAV) 2/8-U6-shChREBP, the 
scAAV2-LP1-hFIXco backbone vector was restricted 
with BamHI and BbsI and the 3,493-bp (base pair) 
fragment was isolated and ligated. Restriction with 
BamHI and Bbsl removed hFIXco and partially deleted 
the LP1 promoter, and the U6 promoter driving the 
expression of the construct was cloned into the vector 
in antisense orientation. Short hairpin RNA (shRNA) 
construct directed against ChREBPα/β and scramble 
construct were ordered as oligonucleotides (shRNA; 
5′-aat tcA AAA AAT GTA GTT TGA AGA TGT 
GGG TCT CGA GAC CCA CAT CTT CAA ACT 
ACA TC-3′ and 3′-ggc caG ATG TAG TTT GAA 
GAT GTG GGT CTC GAG ACC CAC ATC TTC 
AAA CTA CAT TTT TT-5′, scramble; 5′-aat tcG 
TTG TAA GTG GAG GTT TAA GTC TCG AGA 
CTT AAA CCT CCA CTT ACA ACA CCG GT-3′ 
and 3′-ggc caA CCG GTG TTG TAA GTG GAG 
GTT TAA GTC TCG AGA CTT AAA CCT CCA 
CTT ACA AC-5′) and cloned into the vector using 
EcoRI and AgeI. Production, purification, and titration 
of these AAV2/8 viruses encoding the shRNA directed 
against ChREBPα and ChREBPβ and the scrambled 
control were performed as described.(16) Mice were 
injected with 5  ×  1012 virus particles per mouse and 
sacrificed 30 days after virus administration.
IMMoRtalIZeD HUMaN 
HepatoCyte glUCoSe 
StIMUlatIoN aND tRaNSIeNt 
tRaNSFeCtIoN aSSayS
For glucose stimulation, immortalized human hepato-
cyte (IHH) cells(17) were glucose-deprived in Dulbecco’s 
modified Eagle’s medium (Thermo Scientific, Landsmeer, 
The Netherlands) without glucose, supplemented 
with 1% penicillin/streptomycin, 0.1% fatty-acid–free 
bovine serum albumin, 16 mU/mL of insulin, 2 mM of 
GlutaMAX (Thermo Scientific) and 1 mM of glucose 
for 16 hours. Cells were subsequently incubated with 
low (1 mM) or high (11 mM) glucose concentrations 
for 24 hours. For transient transfection assays, IHH 
cells were transfected for 48 hours using Lipofectamine 
RNAiMAX Reagent (Thermo Scientific), according to 
the manufacturer’s protocol, with 50 nM of ChREBP 
small interfering RNAs (siChREBP)(18) or control 
small interfering RNA (siRNA; #12935-100; Thermo 
Scientific) in Williams E medium containing 2 mM of 
glutamine and supplemented with 2% fetal calf serum, 
20 mU/mL of insulin, and 50 nM of dexamethasone.
aNalytICal pRoCeDUReS
Blood glucose was measured using a One Touch Ultra 
glucose meter (LifeScan, Inc., Milpitas, CA). Plasma 
insulin and glucagon were analyzed using commercially 
available enzyme-linked immunosorbent assays (Chrystal 
Chem, Downers Grove, IL and Alpco Diagnostics, 
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Salem, NH, respectively). To quantify plasma plant ste-
rols, plasma lipids were extracted according to Folch 
lipid extraction,(19) methanolyzed, silylated, and analyzed 
with gas chromatography (GC). Commercially available 
kits were used to analyze plasma levels of triglycerides 
(Roche, Mannheim, Germany) and plasma levels of 
total and free cholesterol (Roche and DiaSys, Holzheim, 
Germany, respectively). Hepatic glycogen and G6P con-
tent was determined as described.(20) Plasma and biliary 
bile acid composition were quantified using liquid chro-
matography-mass spectrometry; fecal bile acid composi-
tion was quantified using capillary GC as described.(21) 
The hydrophobicity index of biliary bile acids was calcu-
lated according to Heuman.(22) Fecal cholesterol and its 
derivatives were trimethylsilylated with pyridine, N,O-
Bis(trimethylsilyl) trifluoroacetaminde, and trimethyl-
chlorosilane (ratio 50:50:1) and quantified by GC.
geNe eXpReSSIoN aNalySIS
Total RNA was isolated using TRI-Reagent (Sigma-
Aldrich Corp., St. Louis, MO). Complementary DNA 
was obtained by reverse transcription and amplified 
using primers and probes listed in Supporting Table 
S6. mRNA levels were calculated based on a dilution 
curve, expressed relative to 36b4 for liver and 18S for 
IHH cells, and normalized to their controls.
taRgeteD pRoteoMICS
Targeted proteomics was applied in homoge-
nized liver tissue by the isotopically labeled peptide 
standards (G6PC; GLGVDLLWTLEK, CYP8B1; 
VFGYQSVDGDHR, ChREBP; LGFDTLHGLVS-
TLSAQPSLK, CYP7A1; LSSASLNIR, oxysterol 
7α-hydroxylase [CYP7B1]; YITFVLNP FQYQYVTK, 
sterol 27-hydroxylase [CYP27A1]; LYPVVPTNSR, 
cytochrome P450, family 2, subfamily c, polypeptide 
70 [CYP2C70]; TDSSLLSR), containing 13C-labeled 
lysine/arginine (PolyQuant GmbH, Bad Abbach, 
Germany), according to the workflow described.(21) 
The following alterations were made: Lipids were 
extracted from liver homogenates with diethyl ether 
before the proteomics workflow and the concen-
trations were related to the total peptide content, 
which was determined by a colorimetric peptide assay 
after tryptic digestion and SPE cleanup (Thermo 
Scientific). Concentrations of endogenous peptides 
were calculated from the known concentration of the 
standard and expressed in fmol/µg of total peptide and 
expressed relative to the values in the control group.
Cell RepoRteR aSSayS
CV1 cells (ATCC) were transiently transfected 
using FuGENE 6 Transfection Reagent (Promega, 
Leiden, The Netherlands). pCMVS4/ChREBPα, 
pCMVS4/ChREBPβ, and pCMVS4/Mlx (kind gifts 
from M. Herman) were shuttled to pcDNA3.1 using 
cloning PCR. Primers are listed in Supporting Table 
S6. The human or mouse PGL3/Cyp8b1 promoter 
luciferase reporter (–623/+364 bp and –1,582/+115 
bp respectively, kind gifts from J. Chiang) or mini-
mal promoter PGL3/ChREBP luciferase reporter 
(–40/+12; kind gift from H. Towle) was cotransfected 
with pcDNA3.1/ChREBPα, pcDNA3.1/ChREBPβ, 
pcDNA3.1/Mlx, pcDNA3.1/Hnf4α (hepatocyte 
nuclear factor 4 alpha), or a combination for 48 hours. 
Cell lysis and luciferase assays were performed using 
a Dual-Luciferase Reporter Assay System (Promega).
CHRoMatIN 
IMMUNopReCIpItatIoN/qpCR
Chromatin immunoprecipitation (ChIP) analysis 
was performed as described,(23) with the following 
modifications. Before cross-linking with 1% formal-
dehyde, livers were homogenized in PBS and cross-
linked with 0.5 M of di(N-succinimidyl) glutarate for 
45 minutes at room temperature. Immunoprecipitation 
of samples was performed overnight at 4°C with 3 µg 
of ChREBP (Novus), acetylated histone 4 (Ac-H4; 
Millipore), acetylated histone 3 (Ac-H3; Millipore), 
HNF4A (Santa Cruz), or normal rabbit immuno-
globulin G (IgG) antibody (Santa Cruz). DNA was 
purified using the PCR Clean-up Extraction Kit 
(Macherey-Nagel), after which qPCR was performed. 
Primers are listed in Supporting Table S7.
StatIStICal aNalySIS
Statistical analysis was performed using BrightStat 
software. Differences between two or multiple groups 
were tested by Mann-Whitney U test or Kruskal-
Wallis H test followed by post-hoc Conover pair-
wise comparisons, respectively. P values <0.001 (***), 
0.001-0.01 (**), and 0.01-0.05 (*) were considered 
significant. Correlations were analyzed by Spearman’s 
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correlations coefficient using SPSS software (version 
24.0 for Windows; SPSS, Chicago, IL).
Results
HepatIC g6p aCCUMUlatIoN 
MoDIFIeS BIle aCID SyNtHeSIS
To establish the selective impact of intracellular 
glucose on hepatic bile acid synthesis, C57BL/6 mice 
were infused during 6 hours with S4048, a selective 
inhibitor of the G6P transporter, SLC37A4, thereby 
acutely inducing GSD Ib in liver.(24) S4048 reduced 
blood glucose concentrations and increased hepatic 
G6P and glycogen contents, whereas glucagon- 
to-insulin ratios were increased (Supporting Table S1). 
Hepatic mRNA levels of genes involved in bile acid 
synthesis showed a marked increase in Cyp8b1 expres-
sion, whereas Cyp7a1 and Cyp27a1 expression were 
reduced and Cyp7b1 and Cyp2c70 expression remained 
unchanged (Fig. 1A). S4048 infusion did not alter bil-
iary bile acid composition or plasma bile acid levels 
(Fig. 1B and Supporting Fig. S1A). Presumably, the 
time frame of S4048 infusion is too short to translate 
into altered bile acid composition: The cycling time of 
the murine bile acid pool is approximately 4-5 hours, 
and only 5% of biliary bile acids is derived from 
de novo synthesis.(25)
Next, we performed similar analyses in mice with 
sustained hepatic G6P accumulation, that is, fasted 
liver-specific G6pc knockout (L-G6pc−/−) mice,(14) 
which exhibited increased glucagon-to-insulin ratios 
(Supporting Table S1). In these animals, hepatic 
Cyp8b1 mRNA levels were also strongly elevated 
whereas expression of Cyp7a1, Cyp27a1, Cyp7b1, 
and Cyp2c70 was significantly lower as compared to 
L-G6pc+/+ littermates (Fig. 1C). Altered expression of 
bile acid synthesis genes in L-G6pc−/− mice did translate 
into a relative increase in CA and CA-derived bile acids 
(Fig. 1D; Table 1). Similar increases in CA and DCA 
and concomitant decreases in CDCA and CDCA-
derived MCAs were observed in plasma and feces from 
L-G6pc−/− mice (Supporting Fig. S1B,C; Supporting 
Table S2). Biliary bile acid secretion rates and plasma 
bile acid concentrations were not different between 
L-G6pc−/− and L-G6pc+/+ mice (Fig. 1E; Table 1).
Interestingly, hepatic CYP7A1 protein lev-
els, but not Cyp7a1 mRNA levels, were lower in 
L-G6pc−/− mice as compared to WT littermates (Fig. 1F), 
and hepatic CYP7A1 protein levels positively cor-
related with blood glucose levels (Fig. 1G). Similar 
correlations were observed for plasma 7α-hydroxy-4-
cholesten-3-one (C4) levels, the product of CYP7A1 
and a marker of its activity(26) (Fig. 1G). C4 levels 
were significantly lower in fasted L-G6pc−/− mice com-
pared to WT littermates (Supporting Fig. S1D). On 
the other hand, hepatic CYP8B1 mRNA and protein 
levels were significantly increased in L-G6pc−/− mice 
irrespective of the feeding state (Fig. 1H).
ChReBp MeDIateS tHe 
INDUCtIoN oF Cyp8b1 IN 
ReSpoNSe to HepatIC g6p 
aCCUMUlatIoN
To elucidate the mechanism of G6P-dependent con-
trol of Cyp8b1, we performed S4048 infusions in mice 
lacking forkhead box O (FoxO) 1,3,4 expression in 
hepatocytes and in mice with reduced hepatic expres-
sion of the G6P-sensitive transcription factor, ChREBP, 
which is activated in GSD Ia and GSD Ib.(12,24,27) We 
confirmed that FoxOs control basal Cyp8b1 expression,(4) 
and found that the S4048-mediated induction of Cyp8b1 
was absent in L-FoxO1,3,4−/− mice (Fig. 2A). Interestingly, 
induction of Cyp8b1 upon S4048 infusion was also 
abolished in mice with reduced hepatic Chrebpα and 
Chrebpβ expression (Fig. 2A and Supporting Fig. S2B). 
Similar effects were observed on Cyp8b1 mRNA and 
protein levels upon hepatic ChREBP knockdown in 
L-G6pc−/− mice (Fig. 2B,C). As shown above, S4048 
infusion and hepatic G6pc deficiency caused reductions 
in Cyp7a1 expression. However, these reductions were 
not reversed by knockout of FoxOs or knockdown of 
hepatic ChREBP (Supporting Fig. S2A,C,D). Thus, 
ChREBP mediates the induction of hepatic Cyp8b1, 
but not the repression of Cyp7a1, in liver-specific GSD 
Ia and GSD Ib mice.
We also tested whether established transcrip-
tional regulators of Cyp8b1 are altered in response to 
hepatic G6P-ChREBP signaling. Hepatic expression 
of nuclear receptor subfamily 1 group H member 4 
(farnesoid X receptor; Fxr), nuclear receptor subfam-
ily 5 group A member 2 (liver receptor homolog 1; 
Lrh-1), Hnf4a (Hnf4α), and MAF BZIP transcription 
factor G (Mafg) remained largely unaffected upon 
hepatic G6P accumulation (Supporting Fig. S2E,F), 
indicating that these factors cannot explain the 
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FIg. 1. Hepatic G6P accumulation modifies bile acid synthesis. (A) Hepatic mRNA levels of bile acid synthesis genes and (B) biliary 
bile acid composition in C57BL/6 mice infused with S4048 or vehicle (n = 7). (C) Hepatic mRNA levels of bile acid synthesis genes 
in overnight fasted L-G6pc−/− mice and L-G6pc+/+ mice (n = 7-8). (D) Biliary bile acid composition. (E) Biliary bile acid secretion and 
plasma bile acid levels in L-G6pc−/− and L-G6pc+/+ mice (n = 7-8). (F) Hepatic mRNA and protein levels of CYP7A1 in L-G6pc−/− mice 
and L-G6pc+/+ mice in either fed state or after an overnight fast (n = 7-8). (G) Correlation between blood glucose levels and hepatic 
CYP7A1 protein levels and correlation between blood glucose levels and plasma C4 levels in L-G6pc−/− mice and L-G6pc+/+ mice in 
either fed state or after an overnight fast (n = 7-8). (H) Hepatic mRNA and protein levels of CYP8B1 in L-G6pc−/− mice and L-G6pc+/+ 
mice in either fed state or after an overnight fast (n = 7-8). Data represent Tukey box plots. ***P < 0.001; **P < 0.01; *P < 0.05. See also 
Supporting Fig. S1 and Supporting Tables S1, S2, and S3. Abbreviation: BW, body weight.
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induction of Cyp8b1 in response to G6P accumula-
tion. We noted that the expression of some of these 
factors was reduced exclusively when ChREBP was 
knocked down in S4048-treated or L-G6pc−/− mice 
(Supporting Fig. S2E,F), though the biological sig-
nificance of this is unclear. Hepatic nuclear receptor 
subfamily 0, group B, member 2 (small heterodimer 
partner; Shp) mRNA levels were lower in S4048-
treated and L-G6pc−/− mice as compared to their con-
trols, and were further reduced in response to hepatic 
ChREBP knockdown in L-G6pc+/+ and L-G6pc−/− 
mice (Supporting Fig. S2E,F). Thus, Fxr, Shp, Lrh-1, 
Hnf4α, and Mafg mRNA levels did not consistently 
follow the pattern of CYP8B1 expression in response 
to hepatic G6P-ChREBP signaling (Fig. 2A-C and 
Supporting Fig. S2E,F).
Cyp8b1 INDUCtIoN By g6p-ChReBp 
IS Cell aUtoNoMoUS aND 
oCCURS IN HUMaN CellS
To assess whether this G6P-ChREBP–dependent 
modulation of CYP8B1 is conserved in human 
hepatocytes, we exposed IHH cells, that are glucose 
responsive,(17) to high- and low-glucose culture media. 
We also transfected them with siChREBP or scram-
bled siRNAs under conditions of high-glucose expo-
sure. As expected, high glucose induced CHREBPα 
mRNA levels, as well as the expression of its target 
genes, CHREBPβ, L-type pyruvate kinase (L-PK) and 
apolipoprotein C3 (APOC3; Supporting Fig. S2G), 
whereas siChREBP reduced all of these (Fig. 2D). 
Combined with the in vivo data shown above, these 
in vitro findings demonstrate that ChREBP activity 
is necessary and sufficient for CYP8B1 induction by 
intracellular glucose metabolism, in a cell-autonomous 
manner.
On the other hand, CYP7A1 expression in IHHs 
was not similarly regulated. Consistent with pub-
lished data,(9) CYP7A1 mRNA levels were induced 
upon high-glucose exposure (Supporting Fig. S2G). 
However, siChREBP did not reverse this effect; in 
fact, it amplified it (Supporting Fig. S2G). Thus, 
CYP7A1 mRNA levels are induced in response to 
glucose exposure in IHHs, but not through ChREBP. 
CYP7B1 was not regulated by glucose or siChREBP 
taBle 1. Bile Characteristics in Chow-Fed Male l-G6pc−/− Mice and Wt littermates
L-G6pc+/+ L-G6pc−/−
P ValueMedian (Range) Median (Range)
Body weight (g) 28.4 (21.5-29.9) 27.5 (25.3-32.5) 0.645
Bile flow (µL/min/100 g BW) 12.2 (8.5-15.0) 14.6 (12.3-18.5) 0.021
Bile acid secretion (nmol/min/100 g BW) 305.1 (244.3-587.5) 313.3 (229.7-514.5) 0.878
Phospholipid secretion (nmol/min/100 g BW) 81.1 (75.3-164.9) 109.7 (93.2-159.4) 0.038
Cholesterol secretion (nmol/min/100 g BW) 11.6 (9.5-17.1) 12.7 (10.7-18.6) 0.161
Bile acid species secretion (nmol/min/100 g BW)
CA 3.88 (1.18-7.15) 3.13 (0.86-6.07) 0.959
GCA 0.58 (0.21-1.21) 0.45 (0.31-0.75) 0.279
TCA 150.17 (124.91-292.16) 226.74 (164.34-344.06) 0.028
TUDCA 5.11 (3.86-11.26) 3.92 (2.58-7.33) 0.105
TCDCA 2.01 (1.61-4.98) 2.63 (1.32-5.84) 0.645
TDCA 6.59 (3.40-13.85) 9.18 (2.14-15.74) 0.442
THDCA 2.27 (0.56-3.89) 1.40 (0.79-2.17) 0.279
α-MCA 0.40 (0.14-1.48) 0.31 (0.00-1.18) 0.279
Tα-MCA 11.37 (9.18-36.33) 12.48 (6.90-29.22) 0.878
β-MCA 2.65 (0.52-5.13) 0.42 (0.00-1.17) 0.007
Tβ-MCA 117.01 (87.53-212.07) 52.38 (30.24-117.05) 0.002
ω-MCA 2.61 (0.84-7.07) 0.84 (0.38-1.78) 0.005
Abbreviations: BW, body weight; GCA, glycocholic acid; TCA, taurocholic acid; TUDCA, tauroursodeoxycholic acid; TCDCA, 
taurochenodeoxycholic acid; TDCA, taurodeoxycholic acid; THDCA, taurohyodeoxycholic acid; α-MCA, alpha-muricholic acid; 
Tα-MCA, tauro-alpha-muricholic acid; β-MCA, beta-muricholic acid; Tβ-MCA, tauro-beta-muricholic acid; ω-MCA, omega- 
muricholic acid. P values <0.05 are marked in bold.
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(Supporting Fig. S2G), and CYP27A1 is not expressed 
by IHH cells.
HepatIC g6p-ChReBp SIgNalINg 
RegUlateS BIle aCID 
CoMpoSItIoN
Then, we evaluated whether G6P-ChREBP–
dependent induction of Cyp8b1 translated into 
qualitative changes in biliary and plasma bile acids. 
Hepatic G6P accumulation increased the contribution 
of biliary CA and DCA and increased plasma CA and 
DCA levels in L-G6pc−/− mice whereas administra-
tion of shChREBP had the opposite effect (Fig. 2E 
and Supporting Fig. S2H; Supporting Tables S3, S4, 
and S5), consistent with the observed decrease in 
hepatic Cyp8b1 expression (Fig. 2B,C and Supporting 
Fig. S2B). Combined, these data indicate that G6P-
ChREBP induce qualitative changes in biliary and 
plasma bile acid composition through induction of 
hepatic Cyp8b1 expression.
ChReBp DoeS Not DIReCtly 
RegUlate HepatIC Cyp8b1 
tRaNSCRIptIoN
We next investigated whether ChREBP directly 
regulates Cyp8b1 transcription. Analysis of a hepatic 
ChREBP ChIP sequencing (ChIP-seq) data set(28) 
indicated potential regulation of Cyp8b1 by ChREBP. 
Computational analysis revealed three putative 
ChREBP response elements similar to the ChREBP 
consensus sequence (CAYGYGnnnnnCRCRTG) 
and one element with an alternative sequence 
(GGGGGYGGGC) in the mouse Cyp8b1 pro-
moter (Fig. 3A). Cell reporter assays did not show 
transactivation of the murine or human Cyp8b1 pro-
moter by ChREBPα or ChREBPβ, whereas both 
Cyp8b1 reporters used were transactivated by Hnf4α 
(Fig. 3B),(29) and the minimal acetyl-CoA carboxylase 
alpha (acetyl-CoA carboxylase; Acc) promoter(30) did 
show ChREBP responsiveness (Fig. 3B). In agree-
ment with these findings, in vivo ChIP analysis did 
FIg. 2. ChREBP mediates induction of Cyp8b1 in response to hepatic G6P accumulation. (A) Hepatic mRNA levels of Cyp8b1 in 
L-FoxO1,3,4−/− and L-FoxO1,3,4+/+ mice and in C57BL/6 mice treated with either shChREBP or scrambled shRNA, infused with 
S4048 or vehicle (n = 7-8). (B) Hepatic mRNA levels in L-G6pc−/− and L-G6pc+/+ mice, treated with either shChREBP or scrambled 
shRNA (n = 4-6). (C) Hepatic protein levels in L-G6pc−/− and L-G6pc+/+ mice, treated with either shChREBP or scrambled shRNA 
(n = 3). (D) mRNA expression in IHH cells transfected with siChREBP or scramble after high (11 mM) glucose exposure for 24 
hours (n = 6). (E) Biliary bile acid composition in L-G6pc−/− and L-G6pc+/+ mice treated with either shChREBP or scrambled shRNA 
(n = 4-5). Data represent Tukey box plots. ***P < 0.001; **P < 0.01; *P < 0.05 indicates significance compared to scrambled shRNA. 
#P < 0.05 indicates significance compared to WT littermates. See also Supporting Fig. S2 and Supporting Tables S4 and S5.
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not show a strong interaction of ChREBP with the 
putative response elements in the mouse Cyp8b1 pro-
moter whereas S4048 treatment promoted ChREBP 
recruitment to the pyruvate kinase L/R (L-pk) pro-
moter (Fig. 3A,C).(31) Moreover, HNF4α recruit-
ment to the Cyp8b1 and L-pk promoter regions was 
FIg. 3. ChREBP does not directly regulate hepatic Cyp8b1 transcription. (A) Schematic presentation of putative consensus and 
alternative ChREBP response elements within the murine Cyp8b1 promoter. (B) Luciferase activity for the murine and human CYP8B1 
promoter reporter and minimal promoter ACC/chore after transfection with Hnf4α, ChREBPα, and ChREBPβ plasmids (n = 5-6). 
(C) In vivo ChIP analysis of the putative ChREBP response elements in the hepatic Cyp8b1 and L-pk gene and (D) of acetylated 
histone H4 around the hepatic Cyp8b1 gene in mice treated with either shChREBP or scrambled shRNA and infused with S4048 or 
vehicle (n = 7). (E) Hepatic mRNA levels of Acly in C57BL/6 mice treated with either shChREBP or scrambled shRNA, infused with 
S4048 or vehicle (n = 7-8). Data are represented as means ± SEM. ***P < 0.001; **P < 0.01; *P < 0.05 indicates significance compared to 
vehicle controls. ##P < 0.01; #P < 0.05 indicates significance compared to controls treated with scrambled shRNA. See also Supporting 
Fig. S3. Abbreviations: Alt, alternative; chore, carbohydrate response element; Cons, consensus; TSS, transcription start site.
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not altered upon ChREBP knockdown, indicating 
that the effect of ChREBP was likely not mediated 
by increased HNF4α binding to Cyp8b1 (Supporting 
Fig. S3A). We confirmed that acetylated histone 3 
and 4 (H3/4) mainly interacted with the transcribed 
region of the Cyp8b1 promoter (Supporting Fig. S3B 
and Fig. 3D).(32) Interestingly, recruitment of 
Ac-H4 in the promoter region (–1,500 bp) and fur-
ther downstream (+5,000 bp) in the Cyp8b1 gene 
was induced upon hepatic G6P accumulation and 
reduced upon ChREBP knockdown in S4048-
treated mice, whereas we did not observe clear 
changes in binding of Ac-H3 under conditions of 
combined hepatic ChREBP knockdown and G6P 
accumulation (Fig. 3D). Altogether, these findings 
demonstrate that induction of Cyp8b1 expression by 
G6P-ChREBP is associated with increased recruit-
ment of Ac-H4, but not of ChREBP, HNF4α, or 
Ac-H3, to the Cyp8b1 locus. These effects were 
paralleled by a ChREBP-dependent induction of 
ATP citrate lyase (Acly) expression (Figs. 3E and 
2D), the essential enzyme for glucose-induced his-
tone acetylation in vitro.(33)
g6p-ChReBp INCReaSeS BIlIaRy 
BIle aCID HyDRopHoBICIty 
aND ReDUCeS FeCal SteRol 
loSS
A shift in the contribution of CA- versus CDCA-
derived bile acids alters the hydrophobicity of the 
bile acid pool(22) and, in turn, changes the capacity 
for intestinal lipid solubilization and uptake.(1,7,34-36) 
Induction of hepatic Cyp8b1 expression and rela-
tive increase in CA and DCA in L-G6pc−/− mice 
(Fig. 1C,D) increased the hydrophobicity index of the 
biliary bile acids entering the intestine (Fig. 4A) whereas 
hepatic ChREBP knockdown reduced this index 
FIg. 4. G6P-ChREBP increases biliary bile hydrophobicity and reduces fecal sterol loss. (A) Bile hydrophobicity index of bile from 
L-G6pc−/− and L-G6pc+/+ mice and (B) mice treated with either shChREBP or scrambled (Scr) shRNA (n = 7-8). (C) Fecal neutral 
sterol excretion of L-G6pc−/− and L-G6pc+/+ mice (n = 8) and (D) mice treated with either shChREBP or scrambled shRNA (n = 14). 
(E) Plasma campesterol/cholesterol ratios in L-G6pc−/− and L-G6pc+/+ mice treated with either shChREBP or scrambled shRNA 
(n = 3). (F) Correlation between bile hydrophobicity index and normalized fecal neutral sterol excretion and between (G) Chrebpβ 
mRNA levels and bile hydrophobicity index in L-G6pc−/− and L-G6pc+/+ mice and mice treated with either shChREBP or scrambled 
shRNA (n = 7-8). (H) Correlation between Chrebpβ mRNA levels and fecal neutral sterol excretion in L-G6pc−/− and L-G6pc+/+ mice 
(n = 8). Data represent Tukey box plots. ***P < 0.001; **P < 0.01; *P < 0.05 indicates significance compared to WT littermates or 
controls treated with scrambled shRNA. ##P < 0.01 indicates significance compared to WT littermates. See also Supporting Fig. S4. 
Abbreviation: BW, body weight.
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(Fig. 4B). We confirmed that hepatic Cyp8b1 expression 
was positively correlated to biliary bile acid hydropho-
bicity in L-G6pc−/− mice(37) (Supporting Fig. S4A) and 
hypothesized that altered hydrophobicity in response 
to G6P-ChREBP-CYP8B1 signaling impacts intesti-
nal sterol absorption.(34,36) Hepatic Cyp8b1 expression 
indeed negatively correlated with fecal neutral sterol 
excretion(36) (Supporting Fig. S4B). Fecal neutral sterol 
excretion was reduced in L-G6pc−/− mice (Fig. 4C and 
Supporting Fig. S4C) and, as expected, increased upon 
hepatic ChREBP knockdown (Fig. 4D and Supporting 
Fig. S4C). The plasma campesterol/cholesterol ratio, a 
marker of intestinal cholesterol absorption,(38) showed 
similar patterns (Fig. 4E). Bile acid hydrophobicity and 
fecal neutral sterol excretion were found to be nega-
tively correlated (Fig. 4F) and hepatic Chrebpβ mRNA 
expression showed a positive correlation to hydro-
phobicity index (Fig. 4G), whereas it was negatively 
correlated with fecal neutral sterol excretion (Fig. 4H). 
Fecal energy and fatty acid excretion remained 
unchanged in response to hepatic G6P accumulation or 
ChREBP knockdown (Supporting Fig. S4D,E).
Discussion
In the current study, we characterized an import-
ant regulatory role of glucose, independent of insulin, 
in the control of hepatic bile acid synthesis. Using the 
monogenetic disease GSD I as a model to establish 
the contribution of intrahepatic glucose, we show 
that G6P controls hepatic bile acid synthesis through 
ChREBP-dependent induction of Cyp8b1 in mice. 
Our findings furthermore indicate that the G6P-
ChREBP axis regulates hepatic CYP8B1 expression 
through H4 acetylation dynamics. As a consequence, 
G6P-ChREBP signaling increases the relative abun-
dance of CA-derived bile acids and induces physiolog-
ically relevant shifts in bile composition. We confirmed 
that the human CYP8B1 gene is regulated by a similar 
mechanism. Importantly, our work also demonstrates 
the physiological relevance of this regulatory mecha-
nism: The G6P-ChREBP-dependent change in bile 
acid hydrophobicity in mice associates with reduced 
fecal neutral sterol loss and lower plasma campesterol/
cholesterol ratios, compatible with enhanced intestinal 
cholesterol absorption (Fig. 5).
Besides G6P-dependent regulation of CYP8B1, 
we found that hepatic levels of CYP7A1 protein, 
the supposedly rate-controlling enzyme in bile acid 
synthesis,(6) as well as the plasma concentrations of 
its product C4 correlated with circulating glucose 
levels. Several studies have reported altered hepatic 
Cyp7a1 mRNA expression in response to changes 
in hepatic glucose availability.(9,39) We and others 
have shown that type 1 and type 2 diabetic rodents 
FIg. 5. Working model of the mechanism by which intrahepatic glucose controls bile acid synthesis and intestinal cholesterol handling 
in mice. Intrahepatic glucose (G6P) controls bile acid synthesis through a ChREBP-dependent induction of Cyp8b1 by H4 acetylation, 
whereas hepatic Cyp7a1 expression is regulated by blood glucose levels. Hepatic G6P-ChREBP-CYP8B1 hence induces corresponding 
shifts in bile composition, which subsequently promotes intestinal cholesterol absorption.
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exhibit increased hepatic expression of Cyp7a1(39) and 
an enlarged bile acid pool.(40,41) On the other hand, 
prolonged fasting decreases hepatic Cyp7a1 mRNA 
expression in mice, with a concomitant reduction 
of total bile acid pool size,(39) consistent with our 
finding that hypoglycemia is associated with lower 
hepatic CYP7A1 protein levels. These data indicate 
that blood glucose level regulates CYP7A1 protein 
levels independently of hepatic G6P accumulation, 
possibly through its effect on the insulin-to-glucagon 
ratio,(8,9) but independently of hepatic FOXO1,3,4 or 
ChREBP expression (Supporting Fig. S2A-D).
We thus show that hepatic CYP7A1 expression is 
partly controlled by circulating glucose levels, whereas 
intrahepatic glucose (G6P) appears to be the major 
regulator of CYP8B1 expression. Previous studies 
have reported an induction of Cyp8b1 by glucose 
in vitro(9) and an insulin-mediated suppression of the 
gene in vivo.(2,4) We now show, in insulin-sensitive 
mice, that glucose-mediated induction of Cyp8b1 
requires hepatic ChREBP. Importantly, we observed 
that ChREBP-dependent regulation of Cyp8b1 
expression in response to intracellular glucose signal-
ing was rapid (i.e., within 6 hours in S4048-exposed 
mouse liver) and also occurred in cultured human 
hepatocytes (IHH cells). Thus, the observed reduction 
of CYP8B1 mRNA levels upon ChREBP knockdown 
in IHH cells indicates a cell-autonomous relationship 
between ChREBP and CYP8B1 expression that is 
independent of circulating factors or potential changes 
in hepatic inflammation or injury.
Although we did not identify a direct tran-
scriptional regulation of the CYP8B1 promoter by 
ChREBP, the G6P-ChREBP–dependent changes in 
hepatic Cyp8b1 expression were paralleled by altered 
H4 acetylation patterns in the CYP8B1 promoter and 
more downstream in the gene. Increased H4 acetyla-
tion levels in response to hepatic G6P-ChREBP sig-
naling likely promoted chromatin relaxation in these 
regions, resulting in an induction of Cyp8b1 transcrip-
tion. ChREBP is a key determinant of glycolysis and 
a direct transcriptional regulator of ACLY,(28,42) the 
essential enzyme for glucose-induced histone acetyl-
ation.(9,33) In the current study, we observed con-
sistent changes in Acly expression, H4 acetylation 
patterns, and CYP8B1 expression in response to G6P-
ChREBP signaling. In contrast, expression of other 
potential mediators of the G6P-ChREBP–dependent 
Cyp8b1 regulation (i.e., FXR, SHP, LRH-1, HNF4α, 
and MAFG) did not consistently follow the pattern of 
Cyp8b1 expression in response to G6P-ChREBP sig-
naling. We therefore propose that the G6P-ChREBP 
axis controls the CYP8B1-mediated pathway in bile 
acid synthesis through H4 acetylation dynamics.
Hydrophobic bile acids effectively promote the 
absorption of dietary lipids and sterols,(34-36) whereas 
a more hydrophilic bile acid pool is associated with 
enhanced intestinal cholesterol excretion.(21) Our data 
strongly suggest that ChREBP activity contributes to 
cholesterol homeostasis in mice through its effect on 
CYP8B1 and hence on bile acid composition. The 
ChREBP-mediated increase in CA and decrease in 
β-MCA synthesis resulted in more hydrophobic bile that 
was paralleled by reduced fecal neutral sterol excretion. 
Because dietary cholesterol intake (data not shown), bil-
iary cholesterol excretion (Table 1), and jejunal and ileal 
mRNA expression of Niemann-Pick C1-like 1, ATP 
binding cassette subfamily G member 5, ATP binding 
cassette subfamily G member 8, and acetyl-CoA acetyl-
transferase 2 (data not shown) were similar in L-G6pc−/− 
mice and WT littermates, the reduction in neutral sterol 
excretion is most likely related to enhanced fractional 
cholesterol absorption as a consequence of the more 
hydrophobic bile acid pool in L-G6pc−/− mice. We also 
show that normalization of bile composition upon 
hepatic ChREBP knockdown reverses reduced fecal 
neutral sterol excretion, consistent with the phenotype 
of Cyp8b1−/− mice and with the effect of Cyp8b1 inhi-
bition in mice.(34,36,43) However, in contrast to what was 
reported for Cyp8b1−/− mice fed a high-fat diet,(34,36) 
fecal fatty acid and energy loss remained unaltered in 
the current study. In accord with our findings, Cyp8b1 
heterozygous knockout mice displaying an intermedi-
ate phenotype with regard to bile acid pool composi-
tion also did not present changes in fecal calorie loss.(34) 
The absence of a change in fecal excretion of nonste-
rol dietary fat could furthermore be attributed to the 
relatively low fat content of the chow diet used, the 
high efficiency of intestinal fatty acid absorption under 
normal conditions,(44) and the fact that intestinal ste-
rol absorption shows a larger dependency on bile acid 
hydrophobicity as compared to dietary fatty acids.(35) 
Therefore, we conclude that activation of the hepatic 
G6P-ChREBP-CYP8B1 axis selectively reduces fecal 
cholesterol excretion in chow-fed mice.
A major difference in bile acid metabolism between 
mice and humans is the presence of MCAs in murine 
bile, attributed to rodent-specific C6 hydroxylation.(45) 
Hepatology, Vol. 70, No. 6, 2019 HOOGERLAND ET AL.
2183
Given that MCAs are very hydrophilic,(22) the human 
bile acid pool is more hydrophobic as compared to 
mice. G6P-ChREBP–mediated induction of Cyp8b1, 
promoting CA synthesis at the expense of dihydroxyl-
ated CDCA, would result in a more hydrophilic, rather 
than a more hydrophobic, bile acid pool in humans, 
with a potentially opposite effect on intestinal choles-
terol absorption. There are no reports focusing on dis-
turbed bile acid metabolism in GDS Ia patients, yet it 
is well known that bile acid metabolism is perturbed 
in type 2 diabetes.(2,4,5) Although deviations in blood 
glucose are opposite in GSD Ia and diabetes, intrahe-
patic glucose metabolism is enhanced in both diseases 
and the hepatic phenotypes are very similar, render-
ing GSD Ia a “model” for diabetic liver disease.(10-15) 
Type 2 diabetic mice exhibit elevated hepatic Cyp8b1 
expression and a corresponding increase in 12- 
hydroxylated bile acids,(4,41) which has been attributed 
to IR and consequent FOXO activation.(4) Given that 
hepatic ChREBP is also activated in type 2 diabetic 
mice and humans,(46-48) increased G6P-ChREBP sig-
naling potentially contributes to perturbed bile acid 
metabolism in type 2 diabetes. Therefore, our current 
data underscore the need to establish the impact of 
intrahepatic G6P-ChREBP signaling on bile acid 
pool composition in mice with a humanized bile acid 
pool(45) and GSD I patients, as well as its contribution 
to perturbed bile acid metabolism in type 2 diabetes.
In conclusion, we present a mechanism by which 
intracellular glucose controls hepatic bile acid syn-
thesis and intestinal cholesterol handling. The G6P-
ChREBP-CYP8B1 signaling cascade that we have 
identified likely contributes to altered bile acid metab-
olism and its (patho)physiological consequences in 
conditions coinciding with excessive intrahepatic glu-
cose signaling such as GSD I and type 2 diabetes.
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